156 related articles for article (PubMed ID: 21351271)
1. Postmenopausal hormone use and incident ovarian cancer: Associations differ by regimen.
Hildebrand JS; Gapstur SM; Feigelson HS; Teras LR; Thun MJ; Patel AV
Int J Cancer; 2010 Dec; 127(12):2928-35. PubMed ID: 21351271
[TBL] [Abstract][Full Text] [Related]
2. A prospective study of postmenopausal hormone use and ovarian cancer risk.
Danforth KN; Tworoger SS; Hecht JL; Rosner BA; Colditz GA; Hankinson SE
Br J Cancer; 2007 Jan; 96(1):151-6. PubMed ID: 17179984
[TBL] [Abstract][Full Text] [Related]
3. Hormone therapy and ovarian cancer.
Mørch LS; Løkkegaard E; Andreasen AH; Krüger-Kjaer S; Lidegaard O
JAMA; 2009 Jul; 302(3):298-305. PubMed ID: 19602689
[TBL] [Abstract][Full Text] [Related]
4. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort.
Lacey JV; Brinton LA; Leitzmann MF; Mouw T; Hollenbeck A; Schatzkin A; Hartge P
J Natl Cancer Inst; 2006 Oct; 98(19):1397-405. PubMed ID: 17018786
[TBL] [Abstract][Full Text] [Related]
5. Type II diabetes mellitus and the incidence of epithelial ovarian cancer in the cancer prevention study-II nutrition cohort.
Gapstur SM; Patel AV; Diver WR; Hildebrand JS; Gaudet MM; Jacobs EJ; Campbell PT
Cancer Epidemiol Biomarkers Prev; 2012 Nov; 21(11):2000-5. PubMed ID: 22941335
[TBL] [Abstract][Full Text] [Related]
6. Ovarian cancer and menopausal hormone therapy in the NIH-AARP diet and health study.
Trabert B; Wentzensen N; Yang HP; Sherman ME; Hollenbeck A; Danforth KN; Park Y; Brinton LA
Br J Cancer; 2012 Sep; 107(7):1181-7. PubMed ID: 22929888
[TBL] [Abstract][Full Text] [Related]
7. Menopausal hormone replacement therapy and risk of ovarian cancer.
Lacey JV; Mink PJ; Lubin JH; Sherman ME; Troisi R; Hartge P; Schatzkin A; Schairer C
JAMA; 2002 Jul; 288(3):334-41. PubMed ID: 12117398
[TBL] [Abstract][Full Text] [Related]
8. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women.
Lacey JV; Brinton LA; Lubin JH; Sherman ME; Schatzkin A; Schairer C
Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1724-31. PubMed ID: 16030108
[TBL] [Abstract][Full Text] [Related]
9. Colorectal cancer incidence and postmenopausal hormone use by type, recency, and duration in cancer prevention study II.
Hildebrand JS; Jacobs EJ; Campbell PT; McCullough ML; Teras LR; Thun MJ; Gapstur SM
Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):2835-41. PubMed ID: 19843681
[TBL] [Abstract][Full Text] [Related]
10. Endometrial cancer and menopausal hormone therapy in the National Institutes of Health-AARP Diet and Health Study cohort.
Lacey JV; Leitzmann MF; Chang SC; Mouw T; Hollenbeck AR; Schatzkin A; Brinton LA
Cancer; 2007 Apr; 109(7):1303-11. PubMed ID: 17315161
[TBL] [Abstract][Full Text] [Related]
11. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women.
Rodriguez C; Patel AV; Calle EE; Jacob EJ; Thun MJ
JAMA; 2001 Mar; 285(11):1460-5. PubMed ID: 11255422
[TBL] [Abstract][Full Text] [Related]
12. Postmenopausal unopposed estrogen and estrogen plus progestin use and risk of non-Hodgkin lymphoma in the American Cancer Society Cancer Prevention Study-II Cohort.
Teras LR; Patel AV; Hildebrand JS; Gapstur SM
Leuk Lymphoma; 2013 Apr; 54(4):720-5. PubMed ID: 22916741
[TBL] [Abstract][Full Text] [Related]
13. Postmenopausal hormone therapy and lung cancer risk in the cancer prevention study II nutrition cohort.
Rodriguez C; Spencer Feigelson H; Deka A; Patel AV; Jacobs EJ; Thun MJ; Calle EE
Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):655-60. PubMed ID: 18349283
[TBL] [Abstract][Full Text] [Related]
14. Hormone replacement therapy and risk of epithelial ovarian cancer.
Purdie DM; Bain CJ; Siskind V; Russell P; Hacker NF; Ward BG; Quinn MA; Green AC
Br J Cancer; 1999 Oct; 81(3):559-63. PubMed ID: 10507786
[TBL] [Abstract][Full Text] [Related]
15. Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype.
McCullough ML; Patel AV; Patel R; Rodriguez C; Feigelson HS; Bandera EV; Gansler T; Thun MJ; Calle EE
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):73-9. PubMed ID: 18187388
[TBL] [Abstract][Full Text] [Related]
16. Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe.
Stahlberg C; Pedersen AT; Lynge E; Andersen ZJ; Keiding N; Hundrup YA; Obel EB; Ottesen B
Int J Cancer; 2004 May; 109(5):721-7. PubMed ID: 14999781
[TBL] [Abstract][Full Text] [Related]
17. Hormone therapy and risk of ovarian cancer in postmenopausal women: a systematic review and meta-analysis.
Shi LF; Wu Y; Li CY
Menopause; 2016 Apr; 23(4):417-24. PubMed ID: 26506499
[TBL] [Abstract][Full Text] [Related]
18. Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk?
Trabert B; Wentzensen N; Yang HP; Sherman ME; Hollenbeck AR; Park Y; Brinton LA
Int J Cancer; 2013 Jan; 132(2):417-26. PubMed ID: 22553145
[TBL] [Abstract][Full Text] [Related]
19. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
Colditz GA; Hankinson SE; Hunter DJ; Willett WC; Manson JE; Stampfer MJ; Hennekens C; Rosner B; Speizer FE
N Engl J Med; 1995 Jun; 332(24):1589-93. PubMed ID: 7753136
[TBL] [Abstract][Full Text] [Related]
20. Hormone therapy and ovarian borderline tumors: a national cohort study.
Mørch LS; Løkkegaard E; Andreasen AH; Kjær SK; Lidegaard Ø
Cancer Causes Control; 2012 Jan; 23(1):113-20. PubMed ID: 22037908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
